Literature DB >> 6423103

Side effects of disodium aminohydroxypropylidenediphosphonate (APD) during treatment of bone diseases.

C A Mautalen, C A Casco, D Gonzalez, G R Ghiringhelli, C Massironi, G A Fromm, L Plantalech.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6423103      PMCID： PMC1441632          DOI： 10.1136/bmj.288.6420.828-a

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  2 in total

1.  Treatment of Paget's disease with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  W B Frijlink; O L Bijvoet; J te Velde; G Heynen
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321

2.  Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).

Authors:  F J van Breukelen; O L Bijvoet; A T van Oosterom
Journal:  Lancet       Date:  1979-04-14       Impact factor: 79.321
  2 in total
  14 in total

Review 1.  Treatment of patients with Paget's disease of bone.

Authors:  C Roux; M Dougados
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 2.  Adverse effects of bisphosphonates. A comparative review.

Authors:  S Adami; N Zamberlan
Journal:  Drug Saf       Date:  1996-03       Impact factor: 5.606

3.  Long-lasting dermatological lesions after tiludronate therapy.

Authors:  C Roux; V Listrat; B Villette; M Lessana-Leibowitch; D Ethgen; C Pelissier; M Dougados; B Amor
Journal:  Calcif Tissue Int       Date:  1992-04       Impact factor: 4.333

4.  Comparative study of potential for bisphosphonates to damage gastric mucosa of rats.

Authors:  C P Peter; M V Kindt; J A Majka
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

5.  Severe reaction to diphosphonate.

Authors:  R E Gray
Journal:  BMJ       Date:  1988-10-22

6.  Erythroderma after clodronate treatment.

Authors:  I Pajus; P Lestang; F Lioté; A Dryll
Journal:  BMJ       Date:  1993-08-21

7.  Paget's disease of bone: five regimens of pamidronate treatment.

Authors:  T Pepersack; R Karmali; C Gillet; D François; M Fuss
Journal:  Clin Rheumatol       Date:  1994-03       Impact factor: 2.980

Review 8.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

9.  Low dose intravenous 3-amino-1-hydroxypropylidene-1,1-bisphosphonate (APD) for the treatment of Paget's disease of bone.

Authors:  J A Cantrill; H M Buckler; D C Anderson
Journal:  Ann Rheum Dis       Date:  1986-12       Impact factor: 19.103

Review 10.  Management of osteoporosis and Paget's disease. An appraisal of the risks and benefits of drug treatment.

Authors:  C Gennari; R Nuti; D Agnusdei; A Camporeale; G Martini
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.